GADA Italia and Lifetech Scientific Corporation (LSC) have engaged with a long-time agreement for exclusive distribution over the whole national territory.
LSC, established in 1999 in Shenzhen (People’s Republic of China), is one of the most dynamic company in the development, production, and commercialization of minimally invasive interventional medical devices to treat cardiovascular diseases. Its solutions have been recognized as highly innovative and qualified not only in China, where a lot of them have been approved by China Food and Drug Administration (CFDA) and where the company was rated as a National High-Tech Enterprise, but also in Europe and in the North America.
The agreement between GADA and LSC is related to solutions defined by LSC as “Structural Heart”, which include systems of the closure of cardiac intra-cavitary defects and of the left atrial.
The global increased uptake of LSC solutions is driven not only by the excellent quality of its highly technologic devices and by its investments in R&D, but also by its attention to training and education programs and to sharing of clinical outcomes with interventional cardiologists and arhythmologist.
All that, associated with the development pipeline and with the Vision and Mission of LSC, represent the strategic foundation of a partnership which will allow GADA Italia to enrich the supply of minimally invasive interventional medical devices to treat cardiovascular diseases, by defining a shared path towards growth and development.
Lifetech Scientific Corporation: